These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

638 related items for PubMed ID: 21112655

  • 1. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir.
    Reijnders JG, Rijckborst V, Sonneveld MJ, Scherbeijn SM, Boucher CA, Hansen BE, Janssen HL.
    J Hepatol; 2011 Mar; 54(3):449-54. PubMed ID: 21112655
    [Abstract] [Full Text] [Related]

  • 2. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment.
    Fung J, Lai CL, Young J, Wong DK, Yuen J, Seto WK, Yuen MF.
    Am J Gastroenterol; 2011 Oct; 106(10):1766-73. PubMed ID: 21826112
    [Abstract] [Full Text] [Related]

  • 3. Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels.
    Shin JW, Jung SW, Park BR, Kim CJ, Eum JB, Kim BG, Jeong ID, Bang SJ, Lee SH, Kim SR, Park NH.
    J Viral Hepat; 2012 Oct; 19(10):724-31. PubMed ID: 22967104
    [Abstract] [Full Text] [Related]

  • 4. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
    Gish RG, Chang TT, Lai CL, de Man R, Gadano A, Poordad F, Yang J, Brett-Smith H, Tamez R.
    J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117
    [Abstract] [Full Text] [Related]

  • 5. Peginterferon add-on results in more HBsAg decline compared to monotherapy in HBeAg-positive chronic hepatitis B patients.
    Brouwer WP, Sonneveld MJ, Xie Q, Guo S, Zhang N, Zeuzem S, Tabak F, Zhang Q, Simon K, Akarca US, Streinu-Cercel A, Hansen BE, Janssen HL.
    J Viral Hepat; 2016 Jun; 23(6):419-26. PubMed ID: 26403919
    [Abstract] [Full Text] [Related]

  • 6. Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B.
    Hsu CW, Su WW, Lee CM, Peng CY, Chuang WL, Kao JH, Chu HC, Huang YH, Chien RN, Liaw YF.
    J Formos Med Assoc; 2018 Jul; 117(7):588-597. PubMed ID: 29456079
    [Abstract] [Full Text] [Related]

  • 7. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).
    Ning Q, Han M, Sun Y, Jiang J, Tan D, Hou J, Tang H, Sheng J, Zhao M.
    J Hepatol; 2014 Oct; 61(4):777-84. PubMed ID: 24915612
    [Abstract] [Full Text] [Related]

  • 8. Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy.
    Papatheodoridis G, Goulis J, Manolakopoulos S, Margariti A, Exarchos X, Kokkonis G, Hadziyiannis E, Papaioannou C, Manesis E, Pectasides D, Akriviadis E.
    J Hepatol; 2014 Jan; 60(1):62-8. PubMed ID: 24012614
    [Abstract] [Full Text] [Related]

  • 9. Serum hepatitis B surface antigen kinetics in severe reactivation of hepatitis B e antigen negative chronic hepatitis B patients receiving nucleoside/nucleotide analogues.
    Wong GL, Chan HL, Lo AO, Chan HY, Tse CH, Chim AM, Wong VW.
    Antivir Ther; 2013 Jan; 18(8):979-86. PubMed ID: 23744529
    [Abstract] [Full Text] [Related]

  • 10. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ, Rijckborst V, Cakaloglu Y, Simon K, Heathcote EJ, Tabak F, Mach T, Boucher CA, Hansen BE, Zeuzem S, Janssen HL.
    Antivir Ther; 2012 Jan; 17(1):9-17. PubMed ID: 22267464
    [Abstract] [Full Text] [Related]

  • 11. Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E.
    Boglione L, Cardellino CS, De Nicolò A, Cariti G, Di Perri G, D'Avolio A.
    J Med Virol; 2014 Nov; 86(11):1845-50. PubMed ID: 25131947
    [Abstract] [Full Text] [Related]

  • 12. Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir.
    Pan CQ, Hu KQ, Yu AS, Chen W, Bunchorntavakul C, Reddy KR.
    J Viral Hepat; 2012 Mar; 19(3):213-9. PubMed ID: 22329376
    [Abstract] [Full Text] [Related]

  • 13. Loss of intrahepatic HBsAg expression predicts sustained response to peginterferon and is reflected by pronounced serum HBsAg decline.
    Arends P, Rijckborst V, Zondervan PE, Buster E, Cakaloglu Y, Ferenci P, Tabak F, Akarca US, Simon K, Sonneveld MJ, Hansen BE, Janssen HL.
    J Viral Hepat; 2014 Dec; 21(12):897-904. PubMed ID: 24444353
    [Abstract] [Full Text] [Related]

  • 14. Factors associated with serum hepatitis B surface antigen levels and its on-treatment changes in patients under lamivudine therapy.
    Chen J, Wang Z, Zhou B, Wang Y, Hou J.
    Antivir Ther; 2012 Dec; 17(1):71-9. PubMed ID: 22267471
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B.
    Liem KS, van Campenhout MJH, Xie Q, Brouwer WP, Chi H, Qi X, Chen L, Tabak F, Hansen BE, Janssen HLA.
    Aliment Pharmacol Ther; 2019 Feb; 49(4):448-456. PubMed ID: 30689258
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Correlation of serum hepatitis B surface antigen level with response to entecavir in naïve patients with chronic hepatitis B.
    Lee MH, Lee DM, Kim SS, Cheong JY, Cho SW.
    J Med Virol; 2011 Jul; 83(7):1178-86. PubMed ID: 21567421
    [Abstract] [Full Text] [Related]

  • 19. Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss.
    Zoutendijk R, Hansen BE, van Vuuren AJ, Boucher CA, Janssen HL.
    J Infect Dis; 2011 Aug 01; 204(3):415-8. PubMed ID: 21742840
    [Abstract] [Full Text] [Related]

  • 20. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML, Peng CY, Dai CY, Lai HC, Huang CF, Hsieh MY, Huang JF, Chen SC, Lin ZY, Yu ML, Chuang WL.
    PLoS One; 2015 Aug 01; 10(4):e0122259. PubMed ID: 25835020
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.